Background & Objective: Bacterial, contamination of blood components are a significant risk for transfusion reactions. Inherently, platelet concentrates (PCs) are vulnerable to bacterial contamination, due to the storage condition of processed PCs at room temperature, which provide very suitable conditions for the proliferation of microorganisms.The current study aimed at investigating the transfusion associated septic reaction rate in patients with hemato-oncological diseases in Imam Khomeini Hospital, Tehran, Iran, and identifying the contaminating bacteria.Methods: A total of 3056 adult patients of the Cancer Center of Imam Khomeini Hospital in Tehran transfused with PCs were studied based on the clinical symptoms of septic transfusion reaction from June 1, 2010 to May 31, 2011. Patient presented with the criteria of reaction and the residual components were evaluated for bacterial contamination by Bac T/Alert system.Results: Patients with leukemia or lymphoma transfused with random-donor PCs were evaluated the signs and symptoms of transfusion reaction occurred only in 12 (%0.4) cases. Automated cultivation found 3 positive blood cultures. Among these a male recipient was categorized as possible septic transfusion reaction and Citrobacterfreundii was isolated from blood sample.Conclusion: Appropriate clinical utilization of PCs transfusion, and ongoing vigilance to recognize, investigate, promptly treat, and report all suspicious transfusion reactions are necessary to manage the transfusion complication including transfusion-transmitted infections (TTI).

According to a report released by the World Health Organization (WHO), about 118. 5 million people around the world refer to the blood collection centers to donate blood annually, from whom only 32% (1050%) were female donors in 2020 (1). In blood transfusion, the donated blood is tested for the infectious agents and the compatibility of blood groups. However, the gender mismatch is ignored, which can cause some complications. . .

Background: This retrospective study aimed to evaluate the frequency and type of transfusion reactions (TRs) occurring in patients referred to the blood bank of our institute. Hemovigilance is developed to improve the protection and efficacy of blood transfusions. Objectives: Identifying the adverse reactions helps implement necessary measures to mitigate their occurrence and ensure safer transfusion practices. Methods: This was a retrospective analysis conducted on April 1, 2017. TRs related to the administration of blood components were identified based on clinical symptoms and laboratory data. Data were analyzed using descriptive statistics (frequencies, percentages, and means) to determine the distribution and characteristics of adverse TRs. Results: A total of 488 TRs were recorded. These occurred in patients aged 1 - 99 years (mean age: 49.1 years), including 229 (46.92%) males and 259 (53.07%) females. Packed red blood cells accounted for the highest proportion of reactions (358 cases, 73.3%), followed by platelets (86, 17.62%), fresh frozen plasma (42, 8.6%), and cryoprecipitate (2, 0.4%). The most common TR was an allergic reaction (35.45%), followed by a febrile non-hemolytic reaction (33.60%). Transfusion-related acute lung injury (TRALI) accounted for 1.22% of all TRs. Conclusions: Blood transfusion, though vital in clinical care, may lead to adverse reactions, especially in critically ill patients. Many reactions are underreported due to overlapping symptoms with underlying diseases. Early detection and prompt management of acute TRs (ATRs) can minimize complications, but preventive strategies are essential for patient safety.

Background: Patients with thalassemia major require frequent blood transfusions. Blood transfusion can lead to the adverse reactions. Reporting and evaluating the transfusion reactions are among the goals of implementing the hemovigilance system to improve blood recipients’ safety. This study aimed to compare the transfusion reactions in the thalassemia patients before and after implementation of the hemovigilance system in the Shahid Sadoughi Hospital in Yazd (Iran). Materials and Methods: In this historical cohort study conducted in 2018, the data of 87 patients with thalassemia major including age, sex, the total number of blood transfusions before and after the implementation of hemovigilance system, information about the occurrence of blood transfusion reactions, type, and severity of each reaction were recorded in the questionnaire. Paired-Samples T-test and Chi-Square test were used for data analysis. Results: The mean age of the participants was equal to 19. 69± 8. 41 years old and 52% of them were male. The age of onset of transfusion was 14. 3± 16. 62 months with a range of 2-96 months. The relative frequency of transfusion reactions in the thalassemia patients was 0. 74% and 0. 81%, respectively before and after implementation of the hemovigilance system. Allergic (54%) and non-hemolytic febrile reactions (23%) were the most frequent transfusion reactions. Severe and life-threatening reactions were reported more frequently after implementation of the hemovigilance system compared to pre-implementation (p=0. 007). Totally, 8% of the reactions were hemolytic reactions and 7. 5% of the patients had unexpected alloantibodies identified after implementation of the hemovigilance system. Conclusion: Documentation and reporting of the transfusion reactions after implementation of the hemovigilance system have resulted in reporting of more severe reactions and determination of the clinically significant alloantibodies. Therefore, prevention of the subsequent reactions and increasing the safety of the blood transfusion for the thalassemia patients could be provided, emphasizing the continuation of the system.